Press releases

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) p...

02 March 2020

ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the initiation of a study in par...

27 February 2020

GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma

24 February 2020

U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer

The application is supported by data from the PRIMA study (ENGOT-OV26/GOG-3012), which demonstrated clinically-meaningful outcomes of niraparib treatment in the first-line maint...

17 February 2020

FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States

U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an over-the-counter (OTC) pr...

05 February 2020

GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)

Total EPS 93.9p; +27% AER; +23% CER; Adjusted EPS 123.9p +4% AER, +1% CER

03 February 2020

CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus

GSK to make adjuvant technology available to support rapid development of candidate vaccines

27 January 2020

GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development

GSK announced that it has licensed its M72/AS01E3 tuberculosis disease (TB) vaccine.

21 January 2020

US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma

Belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients

Press releases

Filter by:

GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)

GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer

Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19

Voltaren Arthritis Pain and the Arthritis Foundation Announce Multi-Year Partnership to Help People Living with Osteoarthritis

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

Update on GSK actions to support the global response to COVID-19

GSK appoints Charles Bancroft to the Board as a Non-Executive Director

ViiV Healthcare announces first global regulatory approval of CABENUVA; the first complete, long-acting, regimen for the treatment of HIV

ViiV Healthcare presents positive long-term data from phase III study demonstrating efficacy and safety of cabotegravir and rilpivirine, its investigational, long-acting, injectable treatment regimen in adults living with HIV-1

ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing

ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership

FDA approves GSK’s Advil Dual Action with Acetaminophen for over-the-counter use in the United States

ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV

GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma

U.S. FDA accepts GSK’s sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer

FDA approves GSK’s Voltaren Arthritis Pain for over-the-counter use in the United States

GSK delivers 2019 sales of £33.8 billion +10% AER, +8% CER (Pro-forma +4% CER*)

CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus

GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development

US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma

Find out more about us

About us

Products

Research